32.88

0.12% -0.04

Zenas Biopharma Inc (ZBIO)

Overview News Price History Discussions Forecast

Zenas Biopharma Inc stock is traded at $32.88, with a volume of 452.69K. It is down -0.12% in the last 24 hours and up +4.65% over the past month. Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.

Previous Close:

$32.92

Open:

$32.66

24h Volume:

452.69K

Relative Volume:

0.55

Market Cap:

$2.14B

Revenue:

$10.00M

Net Income/Loss:

$-425.15M

P/E Ratio:

-3.6146

EPS:

-9.0964

Net Cash Flow:

$-210.48M

1W Performance:

+5.15%

1M Performance:

+4.65%

6M Performance:

+27.34%

1Y Performance:

+93.64%

1-Day Range:

$32.38

$33.29

1-Week Range:

$29.88

$33.66

52-Week Range:

$13.50

$44.60

Zenas Biopharma Inc Stock (ZBIO) Company Profile

Name

Zenas Biopharma Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

857-271-2954

Address

852 WINTER STREET, SUITE 250, WALTHAM

Employee

167

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

ZBIO's Discussions on Twitter

Compare ZBIO vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ZBIO Zenas Biopharma Inc	32.88	2.06B	10.00M	-425.15M	-210.48M	-9.0964
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-05-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-20-25	Initiated	Wedbush	Outperform
Feb-04-25	Initiated	Wolfe Research	Outperform
Dec-16-24	Initiated	H.C. Wainwright	Buy
Nov-05-24	Initiated	Rodman & Renshaw	Buy
Oct-08-24	Initiated	Citigroup	Buy
Oct-08-24	Initiated	Guggenheim	Buy
Oct-08-24	Initiated	Jefferies	Buy
Oct-08-24	Initiated	Morgan Stanley	Overweight

View All

Zenas Biopharma Inc Stock (ZBIO) Latest News

Aug 19, 2026

Zenas BioPharma (ZBIO) holder sells 673,755 shares in open-market trade - Stock Titan

Aug 19, 2026

Zenas BioPharma (ZBIO) affiliate plans August 2026 share sale - Stock Titan

Aug 19, 2026

Zenas BioPharma (ZBIO) Institutional Ownership 2026 - MarketBeat

Aug 19, 2026

Aug 18, 2026

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Aug 18, 2026

New Zenas BioPharma hires receive stock awards vesting through 2030 - Stock Titan

Aug 18, 2026

HC Wainwright Predicts Higher Earnings for Zenas BioPharma - MarketBeat

Aug 18, 2026

Aug 17, 2026

SR One's stake in Zenas BioPharma (ZBIO) drops over 1 point without selling - Stock Titan

Aug 17, 2026

Morgan Stanley Maintains Zenas BioPharma(ZBIO.US) With Hold Rating, Raises Target Price to $32 - Moomoo

Aug 17, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 17, 2026

Aug 15, 2026

ZBIO Q1 2026 Earnings: Narrower-than-Expected Loss Signals Cost Discipline for Clinical-Stage BiotechDividend Growth Analysis - Vinanet

Aug 15, 2026

Walleye Capital LLC Takes $5.31 Million Position in Zenas BioPharma, Inc. $ZBIO - MarketBeat

Aug 15, 2026

Aug 14, 2026

Zenas BioPharma's (ZBIO) Buy Rating Reaffirmed at Guggenheim - MarketBeat

Aug 14, 2026

Zenas BioPharma's (ZBIO) Outperform Rating Reiterated at Wedbush - MarketBeat

Aug 14, 2026

Zenas BioPharma (ZBIO) Is Down 9.2% After Wider Losses And Leadership ChangesWhat's Changed - simplywall.st

Aug 14, 2026

Zenas BioPharma, Inc. Announces Chief Financial Officer Changes, Effective September 30, 2026 - marketscreener.com

Aug 13, 2026

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 6.6% on Disappointing Earnings - MarketBeat

Aug 13, 2026

Zenas BioPharma Q2 Results: EPS Misses, Sales Fall 95% - scanx.trade

Aug 13, 2026

Zenas BioPharma, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 13, 2026

Form 8K Zenas Biopharma Inc For: 13 August By Investing.com - Investing.com Canada

Aug 13, 2026

Zenas BioPharma's Q2 Net Loss Widens; CFO to Step Down - marketscreener.com

Aug 13, 2026

Earnings Flash (ZBIO) Zenas BioPharma Posts Q2 Loss $1.77 a Share, vs. FactSet Est of $1.12 Loss - marketscreener.com

Aug 13, 2026

Zenas BioPharma, Inc. 2026: Revenue $1M, Net income ($111.46M), EPS ($1.77) — 10-Q Summary - TradingView

Aug 13, 2026

Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times

Aug 13, 2026

Earnings Flash (ZBIO) Zenas BioPharma, Inc. Reports Q2 Revenue $1.0M - marketscreener.com

Aug 13, 2026

Zenas BioPharma Reports $111.5 Million Second-Quarter Net Loss - Quiver Quantitative

Aug 13, 2026

Aug 12, 2026

Zenas BioPharma (ZBIO) Slides 3.55% to $31.29 as Biotech Sentiment Turns CautiousTotal Put Call - dars.gov.et

Aug 12, 2026

Zenas BioPharma (ZBIO) Edges Higher to $32.44 as Biotech Momentum BuildsMA Cross Alert - Vinanet

Aug 12, 2026

Aug 11, 2026

Zenas BioPharma (ZBIO) Rises 1.41% to $32.44 as Shares Hold Above Key SupportSynthetic Long - vinanet.vn

Aug 11, 2026

Aug 08, 2026

Zenas BioPharma (ZBIO) Holds Gains Above $32 as Bullish Momentum BuildsIndex Put Call - dars.gov.et

Aug 08, 2026

Aug 07, 2026

ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, In - The National Law Review

Aug 07, 2026